Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited covers the month of January 2019, with a specific report date of January 7, 2019. The filing announces the determination of subscription requirements for issuing new Takeda shares as part of the consideration for the proposed acquisition of Shire plc.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. Instead, it details specific transaction values related to the Shire acquisition:
- Number of new Takeda shares to be issued: 770,303,013 shares
- Amount per share to be paid in: JPY 7,601
- Value of contributed property (Shire shares): JPY 5,855,073,208,821.12
- Number of Shire shares contributed: 918,120,398 ordinary shares
Material Changes
The material change reported is the formal determination of the share issuance mechanics for the Shire acquisition, authorized by a resolution at the extraordinary shareholders meeting held on December 5, 2018. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing confirms the date of contribution for the new shares as January 8, 2019. It notes that the actual amounts of capital and capital reserves to be increased will be reported accordingly, calculated based on the Rules of Corporate Accounting. No specific guidance, outlook, or risk factors beyond the transaction details are provided in this document.
Important Facts for Investors to Verify
- Confirmation that the Shire acquisition transaction proceeds as scheduled following this determination.
- The final calculation of the increase in stated capital and capital reserves, which is subject to rounding rules.
- Impact of the 770,303,013 new share issuance on existing shareholder dilution.
- Regulatory approvals required for the contribution of Shire shares valued at approximately JPY 5.86 trillion.